PHAR News

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

Pharming Group to participate in September investor conferences

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bronstein, Gewirtz & Grossman, LLC (PHAR) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pharming Group N.V. (PHAR) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pharming Group N.V. (PHAR) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pharming Group N.V. (PHAR) and Encourages Shareholders to Learn More About the Investigation

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

Pharming Group N.V. (PHAR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation